Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.34 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 4/20 | 0.33 |
| ▸ | BTK | Q06187 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3306361 | 0.86 | ALDH1A1 (0.58) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL3301738 | 0.81 | ALDH1A1 (0.55) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL10025187 | 0.80 | KDM4E (0.74) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL3303540 | 0.76 | ALDH1A1 (0.53) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL3303543 | 0.75 | ALDH1A1 (0.61) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL3306043 | 0.73 | KDM4E (0.50) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL3970266 | 0.73 | ALDH1A1 (0.54) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL3305186 | 0.73 | KDM4E (0.50) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL3300936 | 0.73 | ALDH1A1 (0.46) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL10059359 | 0.73 | ALDH1A1 (0.54) | ALDH1A1KDM4ECYP1A2HPGDBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099719-A1 | COMPOSITION AND METHOD FOR TREATING PROTEINURIA | DIEREPHARMA, INC. (US) | 2010-04-22 | — | — | US | claimed |
| US-20090258911-A1 | COMPOSITION AND METHOD FOR TREATING FIBROTIC DISEASES | TAO LI JIAN | 2009-10-15 | — | — | US | claimed |
| US-20090005424-A9 | Composition and Method for Treating Fibrotic Diseases | TAO LI J | 2009-01-01 | — | — | US | claimed |
| EP-1878428-A1 | 1-(SUBSTITUTED PHENYL)-5- METHYL- 2 - (1H) PYRIDONE IN THE MANUFACTURE OF MEDICAMENTS FOR TREATING FIBROSIS IN ORGANS OR TISSUES | Xiangya Hospital of Central South University (CN) | 2008-01-16 | — | — | EP | claimed |
| US-20070203203-A1 | Composition and Method for Treating Fibrotic Diseases | TAO LI J | 2007-08-30 | — | — | US | claimed |
| US-20100099719-A1 | COMPOSITION AND METHOD FOR TREATING PROTEINURIA | DIEREPHARMA, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20090258911-A1 | COMPOSITION AND METHOD FOR TREATING FIBROTIC DISEASES | TAO LI JIAN | 2009-10-15 | — | — | US | disclosed |
| US-20090005424-A9 | Composition and Method for Treating Fibrotic Diseases | TAO LI J | 2009-01-01 | — | — | US | disclosed |
| US-20080319027-A1 | Composition and Method for Treating Fibrotic Diseases | TAO LI JIAN | 2008-12-25 | — | — | US | disclosed |
| EP-1878428-A1 | 1-(SUBSTITUTED PHENYL)-5- METHYL- 2 - (1H) PYRIDONE IN THE MANUFACTURE OF MEDICAMENTS FOR TREATING FIBROSIS IN ORGANS OR TISSUES | Xiangya Hospital of Central South University (CN) | 2008-01-16 | — | — | EP | disclosed |
| US-20070203203-A1 | Composition and Method for Treating Fibrotic Diseases | TAO LI J | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099719-A1 | COMPOSITION AND METHOD FOR TREATING PROTEINURIA | REN, PTPRF, PPM1F | ALDH1A1 341/4885KDM4E 280/4885CYP1A2 837/4885 |
| US-20090005424-A9 | Composition and Method for Treating Fibrotic Diseases | COL1A1, COL2A1, MMP1 | ALDH1A1 485/4885KDM4E 317/4885CYP1A2 557/4885 |
| US-20080319027-A1 | Composition and Method for Treating Fibrotic Diseases | COL1A1, COL2A1, MMP1 | ALDH1A1 485/4885KDM4E 317/4885CYP1A2 557/4885 |
| US-20090258911-A1 | COMPOSITION AND METHOD FOR TREATING FIBROTIC DISEASES | COL1A1, COL2A1, MMP1 | ALDH1A1 485/4885KDM4E 317/4885CYP1A2 557/4885 |
| US-20070203203-A1 | Composition and Method for Treating Fibrotic Diseases | COL1A1, COL2A1, MMP1 | ALDH1A1 485/4885KDM4E 317/4885CYP1A2 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.